Eltrombopag is a non-peptide thrombopoietin receptor agonist. Eltrombopag has originally been developed for
conditions where therapy for thrombocytopenia is needed. Secondary to eltrombopag have been reported thrombotic
events, chest pain, acute renal failure, neutropenia, ascites, retinal exudates, antiphospholipid syndrome. In this case, we
present a 53 year-old patient who had diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) for 30 years with
splenectomy. He’s still having low thrombocyte counts despite the classical ITP therapy. He was treated with eltrombopag
for the last 2 months and had inferior myocardial infarction despite that having no additional risk factors for coronary
Keywords: Eltrombopag, idiopathic thrombocytopenic purpura, myocardial infarction, thrombosis.
Rights & PermissionsPrintExport